Drug intelligence / Profile preview

GKIND017A

Development stage: Preclinical
Lead developer: China Resources Guokang
Modality: Small Molecules

Overview

GKIND017A is a small molecule modulator of peroxisome proliferator-activated receptors alpha and delta (PPARα/δ) currently in preclinical development by China Resources Guokang Pharmaceutical. It is being investigated for the treatment of non-alcoholic fatty liver disease (NAFLD). While most PPAR-targeted therapies for metabolic liver diseases act as agonists to promote lipid oxidation and insulin sensitivity, GKIND017A is identified in sponsor materials as a PPARα/δ inhibitor. The compound is currently classified as a preclinical candidate.

Targets

PPARD (Peroxisome proliferator–activated receptor delta)PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on GKIND017A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GKIND017A.

Explore the full profile